Jury Says BGI Owes Illumina $8M For Infringing DNA Patents
A California federal jury determined Tuesday that four out of five of Illumina's patents behind its next-generation genome-sequencing technology were valid, finding that Illumina's Chinese rival BGI Genomics and its subsidiaries willfully...To view the full article, register now.
Already a subscriber? Click here to view full article